Artwork

Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

A Dual Approach to Combatting Hepatitis... Dr. Marianne De Backer, CEO at Vir Biotechnology

19:52
 
Distribuie
 

Manage episode 428175792 series 3360496
Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans.

  continue reading

102 episoade

Artwork
iconDistribuie
 
Manage episode 428175792 series 3360496
Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans.

  continue reading

102 episoade

すべてのエピソード

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință